{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T06:50:44Z","timestamp":1763016644906},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Academy of Child &amp; Adolescent Psychiatry"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1097\/01.chi.0000215347.93902.3e","type":"journal-article","created":{"date-parts":[[2006,5,22]],"date-time":"2006-05-22T09:43:48Z","timestamp":1148291028000},"page":"720-728","source":"Crossref","is-referenced-by-count":29,"title":["Single-Dose Pharmacokinetics and Safety of Ziprasidone in Children and Adolescents"],"prefix":"10.1016","volume":"45","author":[{"given":"FLOYD R.","family":"SALLEE","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JEFFREY J.","family":"MICELI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"THOMAS","family":"TENSFELDT","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LISA","family":"ROBARGE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KEITH","family":"WILNER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"NICK C.","family":"PATEL","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/01.chi.0000215347.93902.3e_bib1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0928-0987(01)00096-3","article-title":"Role of modeling and simulation in phase I drug development","volume":"13","author":"Aarons","year":"2001","journal-title":"Eur J Pharm Sci"},{"key":"10.1097\/01.chi.0000215347.93902.3e_bib2","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994"},{"key":"10.1097\/01.chi.0000215347.93902.3e_bib3","first-page":"353","article-title":"An analysis of the time-relations of electrocardiograms","volume":"7","author":"Bazett","year":"1920","journal-title":"Heart"},{"key":"10.1097\/01.chi.0000215347.93902.3e_bib4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/01.jcp.0000084028.22282.f2","article-title":"Ziprasidone metabolism, aldehyde oxidase, and clinical implications","volume":"23","author":"Beedham","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"10.1097\/01.chi.0000215347.93902.3e_bib5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/01.chi.0000145372.61239.bb","article-title":"Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study","volume":"44","author":"Blair","year":"2005","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1097\/01.chi.0000215347.93902.3e_bib6","doi-asserted-by":"crossref","first-page":"967","DOI":"10.4088\/JCP.v62n1209","article-title":"Neuroleptic-related dyskinesias in children and adolescents","volume":"62","author":"Connor","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1097\/01.chi.0000215347.93902.3e_bib7","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.0954-6820.1920.tb18266.x","article-title":"Die systolendauer im elektrokardiogramm bei normalen menschen und bie herzkranken","volume":"53","author":"Fridericia","year":"1920","journal-title":"Acta Med Scand"},{"key":"10.1097\/01.chi.0000215347.93902.3e_bib8","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1517\/14656566.2.10.1655","article-title":"Ziprasidone: profile on safety","volume":"2","author":"Goodnick","year":"2001","journal-title":"Expert Opin Pharmacother"},{"key":"10.1097\/01.chi.0000215347.93902.3e_bib9","author":"Guidance for Industry"},{"key":"10.1097\/01.chi.0000215347.93902.3e_bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/j.1875-9114.1998.tb03820.x","article-title":"The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone","volume":"18","author":"Hamelin","year":"1998","journal-title":"Pharmacotherapy"},{"key":"10.1097\/01.chi.0000215347.93902.3e_bib11","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1007\/BF00442557","article-title":"Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age","volume":"99","author":"Haring","year":"1989","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1097\/01.chi.0000215347.93902.3e_bib12","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/01.jcp.0000104913.75206.62","article-title":"A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition","volume":"24","author":"Harrigan","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"10.1097\/01.chi.0000215347.93902.3e_bib13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0378-4347(95)00071-P","article-title":"Development and validation of a high-sensitivity assay for an antipsychotic agent, CP-88059, with solid-phase extraction and narrow-bore high-performance liquid chromatography","volume":"668","author":"Janiszewski","year":"1995","journal-title":"J Chromatogr B Biomed Appl"},{"key":"10.1097\/01.chi.0000215347.93902.3e_bib14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0022-3956(98)00023-5","article-title":"New atypical antipsychotic medications","volume":"32","author":"Jibson","year":"1998","journal-title":"J Psychiatr Res"},{"key":"10.1097\/01.chi.0000215347.93902.3e_bib15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0920-9964(99)00053-5","article-title":"Differential olanzapine concentrations by sex in a fixed-dose study","volume":"40","author":"Kelly","year":"1999","journal-title":"Schizophr Res"},{"key":"10.1097\/01.chi.0000215347.93902.3e_bib16","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/01.CHI.0000046860.56865.25","article-title":"The relevance of prolonged QTc measurement to pediatric psychopharmacology","volume":"42","author":"Labellarte","year":"2003","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1097\/01.chi.0000215347.93902.3e_bib17","series-title":"Tourette's Syndrome and Tic Disorders","first-page":"55","article-title":"Clinical assessment of tic disorder severity","author":"Leckman","year":"1988"},{"key":"10.1097\/01.chi.0000215347.93902.3e_bib18","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1177\/070674379804300608","article-title":"Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms","volume":"43","author":"Lewis","year":"1998","journal-title":"Can J Psychiatry"},{"key":"10.1097\/01.chi.0000215347.93902.3e_bib19","series-title":"Simulation for Designing Clinical Trials: A Pharmacokinetic-Pharmacodynamic Modeling Perspective","first-page":"289","article-title":"Use of modeling and simulation to optimize dose-finding strategies","author":"Mandema","year":"2003"},{"key":"10.1097\/01.chi.0000215347.93902.3e_bib20","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1046\/j.1365-2125.2000.00147.x","article-title":"Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers","volume":"49","author":"Miceli","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1097\/01.chi.0000215347.93902.3e_bib21","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.clinthera.2004.12.003","article-title":"Metabolic risk during antipsychotic treatment","volume":"26","author":"Newcomer","year":"2004","journal-title":"Clin Ther"},{"key":"10.1097\/01.chi.0000215347.93902.3e_bib22","first-page":"27","article-title":"What's the best treatment for comorbid ADHD\/bipolar mania?","volume":"4","author":"Patel","year":"2005","journal-title":"Curr Psychiatry"},{"key":"10.1097\/01.chi.0000215347.93902.3e_bib23","series-title":"Thyroxine. Physician's Desk Reference","author":"Physicians' Desk Reference","year":"1997"},{"key":"10.1097\/01.chi.0000215347.93902.3e_bib24","doi-asserted-by":"crossref","first-page":"I9","DOI":"10.1007\/s007870070015","article-title":"Atypical neuroleptics in child and adolescent psychiatry","volume":"9","author":"Remschmidt","year":"2000","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1097\/01.chi.0000215347.93902.3e_bib25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","article-title":"Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds","volume":"68","author":"Richelson","year":"2000","journal-title":"Life Sci"},{"key":"10.1097\/01.chi.0000215347.93902.3e_bib26","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/01.CHI.0000046897.27264.46","article-title":"Pharmacodynamics of ziprasidone in children and adolescents: impact on dopamine transmission","volume":"42","author":"Sallee","year":"2003","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1097\/01.chi.0000215347.93902.3e_bib27","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00004583-200003000-00010","article-title":"Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study","volume":"39","author":"Sallee","year":"2000","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1097\/01.chi.0000215347.93902.3e_bib28","first-page":"6","article-title":"The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice","volume":"64","author":"Stahl","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1097\/01.chi.0000215347.93902.3e_bib29","first-page":"129","article-title":"Causes of haloperidol discontinuation in patients with Tourette's disorder: management and alternatives","volume":"57","author":"Silva","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"10.1097\/01.chi.0000215347.93902.3e_bib30","first-page":"159","article-title":"Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutic potential","volume":"4","author":"Tandon","year":"1997","journal-title":"J Serotonin Res"},{"key":"10.1097\/01.chi.0000215347.93902.3e_bib31","doi-asserted-by":"crossref","first-page":"15S","DOI":"10.1046\/j.1365-2125.2000.00148.x","article-title":"Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers","volume":"49","author":"Wilner","year":"2000","journal-title":"Br J Clin Pharmacol"}],"container-title":["Journal of the American Academy of Child &amp; Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856709612302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856709612302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T13:45:19Z","timestamp":1707054319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890856709612302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["S0890856709612302"],"URL":"https:\/\/doi.org\/10.1097\/01.chi.0000215347.93902.3e","relation":{},"ISSN":["0890-8567"],"issn-type":[{"value":"0890-8567","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}